Although these results indicate that the transgene per se does not promote cardiac hypertrophy or lifespan at the timepoints analysed, we cannot fully exclude cardiotoxic off-target effects of Cre recombinase under the Myh6 promoter. This evidence concerns the gene MYH6 and cardiac hypertrophy.